Long-term safety study of iptacopan for IgA nephropathy
Treatments studied
Part of Immune system & allergy, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study provides continuing treatment with iptacopan for people with IgA nephropathy who have completed a previous iptacopan trial. It aims to see how safe and tolerable the drug is over a longer period.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have completed a previous iptacopan study for IgA nephropathy.
- Your kidney function must be at least 20 ml/min/1.73m2.
- You need to be up to date on vaccines for meningitis, pneumonia, and Haemophilus influenzae.
- You must be on a supportive care regimen with ACE inhibitors or ARBs, or have a documented allergy or intolerance to these medications.
- You cannot have any other significant urinary tract disorders besides IgA nephropathy.
- You cannot have had acute kidney injury within the last 4 weeks or a rapid decline in kidney function within the last 3 months.
- You cannot have used immunosuppressive drugs or systemic corticosteroids within the last 90 days (or 180 days for rituximab).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if adding iptacopan to standard care can improve kidney health in adults with IgA nephropathy. You may qualify if you have a kidney biopsy confirming IgA nephropathy and your kidney function is stable enough.
This study tests a new medicine called iptacopan to see if it helps children with IgA nephropathy (a kidney disease). Kids who join will receive the study treatment and be monitored for safety and effectiveness.
This study collects real-world information from people with IgA nephropathy who are being treated with one of two medicines, iptacopan or atrasentan. The goal is to understand how these treatments work in everyday practice, which may help improve care for others with the condition.
This Phase 3 trial looks at how well and how safely iptacopan works over the long term for people with C3G or IC-MPGN. You may be able to join if you already finished a specific earlier study and you’re currently healthy enough for long-term treatment.
This study follows people with aHUS who are already taking iptacopan to check how well it continues to work and how safe it is over the long term. You may be asked to keep taking the study medicine and follow extra safety rules, including infection and pregnancy precautions.
This study looks at how well iptacopan works for people with C3G, a kidney disease. It aims to see if the treatment is safe and effective, and includes people who have already taken iptacopan.
Hear when a new Primary IgA Nephropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.